Currently, T-DXd is approved for use in advanced breast cancer with low or overexpression of HER2, HER2-positive gastric cancer, and non-small cell lung cancer.[14] Few clinical studies have assessed the application of T-DXd in cholangiocarcinoma. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.